

PRESS RELEASE



C4Diagnostics raises € 2.3 Million in Series A and brings a US investor to the founding round, to accelerate the deployment of its infectious diseases' diagnostic solutions

January 24th, 2020 –The French biotech company, C4Diagnostics[®], developing innovative in vitro diagnostic tests in the field of infectious diseases, announces that it has raised € 2.3 million in its Series A funding round led by US private investor Andreï Polukhtin, with the participation of French fund CAAP Création and of its historical shareholders, including Région Sud Investissement (advised by Turenne Groupe) and R2V (managed by ACG Management).


C4Diagnostics addresses the growing and global public health issues of antibiotic resistance and infectious diseases' diagnostic by developing and commercializing diagnostic tests that are easy to use for the laboratory and fast and accurate for the patient and healthcare professionals.

This Series A fundraising will strengthen the commercial development of C4Legio™, C4Diagnostics' first product for the diagnosis of Legionellosis. It will also support the development of the product portfolio in the field of urinary infection (C4UTI™) and antimicrobial resistance (C4AST™), two ambitious projects on major public health issues.

"We are particularly happy, with this new fundraising, to welcome a new investor alongside our historical shareholders. The arrival of Andreï Polukhtin in the capital and the Board of C4Diagnostics is a real asset, due to his scientific expertise and his knowledge of the North American market" comments Younes Lazrak, CEO at C4Diagnostics.

"I am exceptionally excited to be a part of the endeavor of C4Diagnostics. This Company's potential for developing ground-breaking technologies that allow for efficient diagnosis of infectious diseases cannot be matched or underestimated. Click Chemistry Tools has enjoyed years of productive collaboration with C4Diagnostics as a distributor, and now we finally can take our business relationship to the next level through my personal investment and my involvement with the Board of Directors" says Andreï Polukhtin, Managing Director at Click Chemistry Tools.

C4Diagnostics' ambition is to become one of the leaders in the field of *in vitro* diagnostics for infectious diseases thanks to its patented versatile technology that will enable a complete range of products to be developed in the long run.



About C4Diagnostics



C4Diagnostics

Based in Marseille, France, C4Diagnostics designs, develops and commercializes innovative in vitro diagnostic tests in the field of infectious diseases. Recipient of numerous awards, C4Diagnostics tests are based on state-of-the-art technology that allows pathogenic microorganisms to become rapidly detectable using their own metabolism. C4Diagnostics aims to become one of the main players in the diagnosis of infectious diseases and disrupt the global market of infectious diseases IVD, by providing the appropriate information to physicians and patients in more sensitive and faster way. C4Diagnostics addresses major public health issues such as infection control and antimicrobial resistance control.

For more information: www.c4diagnostics.com

About Andreï Polukhtin

Andreï Polukhtin is a founder and Managing Director of Click Chemistry Tools, U.S. based company that supplies for over a decade variety of bioconjugation reagents and fluorescent dye all over the World. Dr. Polukhtin has PhD in photochemistry and extensive business experience that helped him to grow CCT into one of the major players in bioconjugation chemistry market. Dr. Polukhtin supports C4Diagnostics through the investment of his private funds.

About CAAP Création



The leading financier of the regional economy, Crédit Agricole Alpes Provence via its "Capital & Innovation" system, which includes the venture capital subsidiary CAAP Création, aims to support economic initiative and innovation in the Bouches du Rhône region, Rhône, Vaucluse and Hautes-Alpes. CAAP Création intervenes in Investment in support of innovative projects with high growth potential and in the financing dedicated to the creation of business. Since its creation in 2006, CAAP Création has supported 130 regional companies.

About Région Sud Investissement



Région Sud Investissement is the regional co-investment fund created in 2010 by Région Sud to support the emergence and development of growing regional companies. The fund is the symbol of the new dynamic that Région SUD wishes to build with companies.

The FIER (13 financial tools for the regional SMEs) gathers a diversity of tools adapted for all stages of development and should allow nearly €300 millions within 3 years to 10,000 companies.


Région Sud Investissement endowed with €120 millions, benefits from the support of Europe: 42% of the €120 millions come from the FEDER. Since July 2011, this fund, advised by Turenne Groupe for the management of its participations, has already invested in 89 regional companies for a total amount of €46,6 millions. Région Sud Investissement has also created an activity of equity loan, for regional start-ups and SMEs, advised by ACG Management, from €15,000 to €200,000.

For more information: www.regionsudinvestissement.com

About Turenne Groupe



Advising Région Sud Investissement, Turenne Group, a leading private equity firm in France, has helped business owners carry out their innovation, development and transfer projects over the last 20 years. As an independent player, the Group managed €1 billion as of 30 June 2019. It employs 62 professionals, including 46 investors, based in Paris, Lille (Nord Capital), Lyon, Marseille and Metz, who provide assistance to more than 250 business representing 33,000 jobs leaders in the healthcare, hospitality, new technologies, distribution or innovative services sectors. Turenne Group advocates a Socially Responsible Investor approach. It provides financial support and runs the Béatrice Denys Foundation for Therapeutic Innovation, which rewards the most successful



projects within French academic medical research, under the auspices of the Foundation for Medical Research.

For more information: www.turennecapital.com

About R2V



R2V is an inter-regional seed fund which finances the start-up of innovative companies based in the South-East of France including Région Sud Provence-Alpes-Côte d'Azur and Auvergne Rhône Alpes in order to consolidate their equity. ACG Management identifies and conducts the investments in the Region Sud Provence-Alpes-Côte d'Azur. With a capital of €25 million, R2V's investment strategy is being rolled out on areas at the intersection of several scientific fields.

About ACG Management



ACG Management, a specialist in investing in unlisted French SMEs, has been assisting companies at all stages of their development (seed capital, venture capital, growth capital and buy out) for 20 years. The company is active in a variety of promising sectors with the aim of bringing out the talents of tomorrow.

It offers a wide range of investment vehicles managed or advised, including funds for the general public (FCPI, FIP) or for professional investors.

ACG Management is one of the major players in the market, thanks to a unique positioning combining independence, innovation, expertise and proximity to the market:

- 956 million raised, managed or advised since the beginning
- 40,000 individual and institutional investors in 69 private equity vehicles,
- 391 companies financed since the beginning,
- A multidisciplinary team of 30 employees, including 14 professionals dedicated to investment based in Marseille, Ajaccio, Bastia, St Denis de la Réunion.

For more information: www.acg-management.fr

Advisors

Mathieu Pointud, Akheos- KPMG Avocats: Advisor of C4Diagnostics

Jean-Marc Soustre, SE13 Advisors: Advisor of C4Diagnostics

Renaud de Blegiers: Attorney of Mr Polukhtin

Press contact

Younes Lazrak

CEO

+33 (0)7 71 79 32 80

Younes.Lazrak@c4diagnostics.com

Ophelie Philipot

Press spokesperson

+33 (0)6 70 07 87 47

Ophelie.Philipot@comopi.tech

